Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant CancersHusain Yar Khan, Asfar S. Azmi, Misako Nagasaka et al.|Cancer Research Communications|2022Cited by 27
Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation TherapyHusain Yar Khan, Asfar S. Azmi, Mandana Kamgar et al.|Advances in Radiation Oncology|2022Cited by 20
Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)Misako Nagasaka, Asfar S. Azmi, Mohammad Asad et al.|Lung Cancer|2021Cited by 15
Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed TherapyElisabeth I. Heath, John L. Marshall, Gary A. Puckrein et al.|Cancer Research Communications|2024Cited by 6
Association between cannabis use and clinical outcomes in patients with solid malignancies receiving immune checkpoint inhibitorsTarik Hadid, Ammar Sukari, Adam Biedny et al.|Therapeutic Advances in Vaccines and Immunotherapy|2024Cited by 3